Evidence map›Paper›PMID 40770581›Full record

ArticleAnnals of intensive care2025

Respiratory management of critically ill pneumocystis pneumonia patients: a multicenter retrospective study.

Florian Reizine, Vicky Stiegler, Romain Lécuyer, Benoit Tessoulin, Marie Gallais, Fabrice Camou, Florent Morio, Anne Cady, Frederic Gabriel, Emmanuel Canet and 5 more

Abstract read
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Florian ReizineService de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, 56000, Vannes, France. florian.reizine@gmail.com.ORCID http://orcid.org/0000-0002-9871-636X
Vicky StieglerDepartment of Infectious Diseases, INSERM, University Hospital of Nantes and Centre d'Investigation Clinique 1413, Nantes, France.
Romain LécuyerUR 1155, Laboratory of Targets and Drugs for Infections and Cancer, IRS2-Nantes Biotech, Nantes, France.
Benoit TessoulinINSERM, U1232, Hematology Department, Nantes University Hospital, CRCI2NA, Nantes University, Nantes, France.
Marie GallaisService de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, 56000, Vannes, France.
Fabrice CamouInternal Medicine and Infectious Disease Unit, Groupe Sud, University Hospital, Bordeaux, France.
Florent MorioCibles et Médicaments des Infections et de l'Immunité, Nantes Université, CHU Nantes, Nantes, France.
Anne CadyDepartment of Microbiology, Centre Hospitalier Bretagne-Atlantique, Vannes, France.
Frederic GabrielService de Parasitologie Mycologie, Centre Hospitalier Universitaire de Bordeaux, 33000, Bordeaux, France.
Emmanuel CanetMedical Intensive Care, University Hospital, Nantes, France.
François RaffiDepartment of Infectious Diseases, INSERM, University Hospital of Nantes and Centre d'Investigation Clinique 1413, Nantes, France.
David BoutoilleDepartment of Infectious Diseases, INSERM, University Hospital of Nantes and Centre d'Investigation Clinique 1413, Nantes, France.
Nahéma IssaInternal Medicine and Infectious Disease Unit, Groupe Sud, University Hospital, Bordeaux, France.
Benjamin GaboritDepartment of Infectious Diseases, INSERM, University Hospital of Nantes and Centre d'Investigation Clinique 1413, Nantes, France. benjamin.gaborit@chu-nantes.fr.
PRONOCYSTIS Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumocystis jirovecii pneumonia (PjP) is a rising cause of acute respiratory failure in immunocompromised patients, often requiring Intensive Care Unit (ICU) admission. However, optimal ventilatory strategies remain unclear.

methodsFor the present study, we conducted an ancillary analysis of the PRONOCYSTIS study, a large multicenter cohort of PjP patients. Patients admitted to the ICUs were compared according to initial respiratory management (High-Flow Nasal Cannula (HFNC), standard Oxygen (SO) or Non-Invasive Ventilation (NIV). A propensity score adjustment [inverse probability of treatment weighting (IPTW) analysis] was implemented to account for potential confounders. The primary outcome was intubation rate. Univariable and multivariable Cox regressions were also used to assess variables associated with survival.

resultsOver the study period, 248 patients with PjP were included in the present analysis. Of those, 70 were treated by HFNC while 118 and 60 received SO and NIV, respectively. HFNC patients had a decreased intubation rate (28.6% versus 45.0% in NIV and 55.4% in SO patients; p = 0.003). When assessing the impact of respiratory management on intubation by IPTW, HFNC remained an independent protective factor (weighted Hazard Ratio (HR) 0.41 (95% CI 0.24-0.69); p < 0.001). While, NIV was not associated with intubation (HR 0.62 (95% CI 0.37-1.02); p = 0.056). Through adjusted survival analysis, long-term corticosteroids treatment (aHR 4.03 (95% CI 2.01-8.08); p < 0.001), Solid tumor (aHR 3.37 (95% CI 1.45-7.86); p = 0.005) and the Sequential Organ Failure Assessment score (aHR 1.24 (95% CI 1.15-1.35); p < 0.001) were found to be independent predictor for death. Initial respiratory support was not associated with survival either in the Cox multivariable analysis or in the IPTW analysis.

conclusionThrough this multicenter observational study of severe PjP patients, although oxygenation strategy was not associated with D90 survival, HFNC support appeared to be associated with a lower intubation rate. Further prospective studies are warranted to refine respiratory management in critically ill PjP patients.

Indexed as

Acute respiratory failureHigh-Flow Nasal CannulaIntensive care unitPneumocystis jirovecii pneumoniaRespiratory managementStandard oxygen

Identifiers

PMID40770581
PMCPMC12328854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.